Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2021-A00362-39 | Other Identifier | 2021-A00362-39 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to collect medical informations and samples from refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax treatment, in order to evaluate the frequency of resistance mechanisms.
The purpose of this study is to collect medical informations and samples (blood, bone marrow and/or lymph node) from refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax treatment, in order to evaluate the frequency of resistance mechanisms (BCL2 mutations, over-expression of other members of the BCL2 protein family and energy metabolism changes).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax | Cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Frequency measurement of BCL2 gene mutations | Frequency measurement of BCL2 gene mutations in a cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax therapy | immediately after the chronic lymphocytic leukemia progression |
| Measure | Description | Time Frame |
|---|---|---|
| Frequency measurement of 1q amplification | Frequency measurement of 1q amplification in a cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax therapy | immediately after the chronic lymphocytic leukemia progression |
| Differential expression of candidate transcripts and proteins |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Patients of their legal guardians refusing to participate
-
Not provided
Not provided
Not provided
Patients with chronic lymphocytic leukemia diagnosis according to iwCLL criteria and who are refractory and/or relapsed disease during or after venetoclax treatment; tumor samples available.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lise Laclautre | Contact | 334.73.754.963 | promo_interne_drci@chu-clermontferrand.fr |
| Name | Affiliation | Role |
|---|---|---|
| Romain GUIEZE | University Hospital, Clermont-Ferrand | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU d'Amiens | Not yet recruiting | Amiens | France |
Not provided
Not provided
Not provided
Not provided
Differential expression of candidate transcripts and proteins (BCL2 protein family, AMP signaling pathway, energy metabolism) in a cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax therapy |
| immediately after the chronic lymphocytic leukemia progression |
| Correlation of resistance mechanisms with clinical staging | Correlation of resistance mechanisms (BCL2 mutation and 1q amplification) with clinical staging, in a cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax therapy | immediately after the chronic lymphocytic leukemia progression |
| Correlation of resistance mechanisms with genomic chronic lymphocytic leukemia features | Correlation of resistance mechanisms (BCL2 mutation and 1q amplification) with genomic chronic lymphocytic leukemia features, in a cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax therapy | immediately after the chronic lymphocytic leukemia progression |
| Progression Free Survival according to resistance mechanisms | Progression Free Survival according to resistance mechanisms (BCL2 mutation and 1q amplification), in a cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax therapy | immediately after the chronic lymphocytic leukemia progression |
| CHU de Besançon | Not yet recruiting | Besançon | France |
|
| Hopital AVICENNE | Not yet recruiting | Bobigny | France |
|
| CHU clermont-ferrand | Not yet recruiting | Clermont-Ferrand | France |
|
| CHU de Clermont Ferrand | Not yet recruiting | Clermont-Ferrand | France |
|
| CHU Grenoble | Not yet recruiting | Grenoble | France |
|
| CHRU de Lille | Not yet recruiting | Lille | France |
|
| Centre LEON BERARD | Not yet recruiting | Lyon | France |
|
| CHU de Montpellier | Not yet recruiting | Montpellier | France |
|
| CHU Nancy | Not yet recruiting | Nancy | France |
|
| Hopital Pitié Salpetrière | Not yet recruiting | Paris | France |
|
| Hopital Haut LEVEQUE | Not yet recruiting | Pessac | France |
|
| CHU de Reims | Recruiting | Reims | France |
|
| IUCT Oncopole | Not yet recruiting | Toulouse | France |
|
| ID | Term |
|---|---|
| D015451 | Leukemia, Lymphocytic, Chronic, B-Cell |
| ID | Term |
|---|---|
| D015448 | Leukemia, B-Cell |
| D007945 | Leukemia, Lymphoid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided